tiprankstipranks
Trending News
More News >

Dynavax sees FY25 adjusted EBITDA ‘at least $75M’ vs. $51.9M in FY24

FY25 HEPLISAV-B net product revenue is expected in the range of $305M to $325M

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue